H.C. Wainwright raised the firm’s price target on Novocure (NVCR) to $38 from $30 and keeps a Buy rating on the shares after the company announced the Phase 3 PANOVA-3 study evaluating Tumor Treating Fields in unresectable, locally advanced pancreatic adenocarcinoma met its primary endpoint by demonstrating a statistically significant median overall survival benefit. The firm, which views pancreatic cancer as “a significant market opportunity,” currently models global peak sales of $1.7B by 2037, is estimating a launch in 2026 and have increased its view of the odds of success to 70% from 20% previously.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- Novocure price target raised to $33 from $28 at Leerink
- Morning Movers: Intel climbs following retirement of CEO Pat Gelsinger
- NovoCure’s TTFields Therapy Shows Promise in PANOVA-3 Trial
- Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint
- Novocure announces PANOVA-3 trial met primary endpoint